Connect with us

Sleep

Cannabis extracts effective in treating chronic insomnia

Participants said they fell asleep faster, slept longer, and experienced improved sleep quality.

Published

on

Those consuming the cannabis extracts reported “significantly lower” Insomnia Severity Index scores

The short-term use of cannabis extracts has been found to improve sleep quality in patients with insomnia.

Plant-derived cannabis extracts were safe and effective for use in patients with chronic insomnia, according to a small placebo-controlled study.

Researchers assessed the use of a sublingual cannabis extract product (ZTL-101, produced by the Australian-based company Zerila Therapeutics) compared to a placebo in 23 subjects with chronic insomnia. 

Extracts contained percentages of plant-derived THC, CBD, and CBN as well as various terpenes. 

The placebo contained the same terpenes, but no cannabinoids, extracted from the same cannabis plant, to match ZTL-101 as closely as possible.

Subjects administered between 0.5ml and 1ml of the product, one hour before going to bed for a period of two weeks. 

Those consuming the cannabis extracts reported “significantly lower” Insomnia Severity Index (ISI) scores than the placebo controlled group.

Participants receiving the extracts said that they fell asleep faster, slept longer, and experienced improved sleep quality. No serious adverse events were reported.

Authors concluded: “This study has demonstrated that ZTL-101, a novel cannabinoid therapy, is well tolerated and improves insomnia symptoms and sleep quality in individuals with chronic insomnia symptoms.

“These improvements, observed over a two-week dosing period, are encouraging and support further investigation of ZTL-101 for the treatment of insomnia in studies with larger sample sizes.”

 

 

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.